BDBM636483 (2RS)-4,4-difluoro-2-(4-fluorophenyl)-N-{4-[(7RS)-5-methyl-4-oxo-3-[(1,3-thiazol-4-yl)amino]-7-(2,2,2-trifluoroethyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-2-yl]pyridin-2-yl}butanamide (Mixture of 4 Stereoisomers)::US20230365554, Example 52::US20230365554, Example 53::US20230365554, Example 54::US20230365554, Example 55::US20230365554, Example 56

SMILES CN1CC(CC(F)(F)F)c2[nH]c(c(Nc3cscn3)c2C1=O)-c1ccnc(NC(=O)C(CC(F)F)c2ccc(F)cc2)c1

InChI Key InChIKey=STQCJZAKVWFOTG-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 636483   

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 3nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 4nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 7.70nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 7.90nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 12nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 13nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 21nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 35nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform alpha(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 59nMAssay Description:CSNK1A1-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetCasein kinase I isoform delta(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 110nMAssay Description:CSNK1D-inhibitory activity of compounds of the present invention in presence of 1 μM adenosine-tri-phosphate (ATP) was quantified employing the ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 1.08E+4nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 2.00E+4nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 2.00E+4nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 2.00E+4nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
The Broad Institute

US Patent
LigandPNGBDBM636483(US20230365554, Example 52 | US20230365554, Example...)
Affinity DataIC50: 2.00E+4nMAssay Description:Recombinant fusion protein of N-terminal Glutathion-S-Transferase (GST) and a fragment of human EGFR (amino acids R669 to A1210), expressed in Sf9 in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
US Patent